Table 4.
Comparison, parameter | n | CV, % | Estimated ratio, % | 90% CI |
---|---|---|---|---|
Riociguat (total) | ||||
Mild vs. normal | ||||
AUCnorm | 31 | 98 | 143 | 87.1–234 |
Cmax, norm | 31 | 29 | 113 | 95.4–134 |
Moderate vs. normal | ||||
AUCnorm | 32 | 98 | 204 | 126–332 |
Cmax, norm | 32 | 29 | 115 | 97.5–136 |
Severea vs. normal | ||||
AUCnorm | 32 | 98 | 144 | 88.6–234 |
Cmax, norm | 32 | 29 | 96.6 | 81.7–114 |
Metabolite M1 (total) | ||||
Mild vs. normal | ||||
AUCnorm | 31 | 39 | 101 | 81.0–127 |
Cmax, norm | 31 | 58 | 76.1 | 55.2–105 |
Moderate vs. normal | ||||
AUCnorm | 32 | 39 | 163 | 131–204 |
Cmax, norm | 32 | 58 | 81.1 | 59.1–111 |
Severea vs. normal | ||||
AUCnorm | 32 | 39 | 175 | 140–218 |
Cmax, norm | 32 | 58 | 86.4 | 63.0–119 |
Riociguat (unbound) | ||||
Mild vs. normal | ||||
AUCu, norm | 31 | 103 | 130 | 78.0–217 |
Cmax, u, norm | 31 | 34 | 103 | 84.8–126 |
Moderate vs. normal | ||||
AUCu, norm | 32 | 103 | 218 | 132–360 |
Cmax, u, norm | 32 | 34 | 123 | 101–149 |
Severea vs. normal | ||||
AUCu, norm | 32 | 103 | 174 | 105–288 |
Cmax, u, norm | 32 | 34 | 117 | 96.2–142 |
Metabolite M1 (unbound) | ||||
Mild vs. normal | ||||
AUCu, norm | 31 | 40 | 94.6 | 75.1–119 |
Cmax, u, norm | 31 | 59 | 70.7 | 50.9–98.2 |
Moderate vs. normal | ||||
AUCu, norm | 32 | 40 | 181 | 144–227 |
Cmax, u, norm | 32 | 59 | 89.7 | 64.9–124 |
Severea vs. normal | ||||
AUCu, norm | 32 | 40 | 233 | 186–293 |
Cmax, u, norm | 32 | 59 | 115 | 83.4–159 |
AUCnorm: area under the plasma concentration–time curve from time 0 to infinity divided by dose of riociguat per kilogram body weight for total riociguat/M1; AUCu, norm: area under the plasma concentration–time curve from time 0 to infinity divided by dose of riociguat per kilogram body weight for unbound riociguat/M1; Cmax, norm: maximum concentration in plasma divided by dose of riociguat per kilogram body weight for total riociguat/M1; Cmax, u, norm: maximum concentration in plasma divided by dose of riociguat per kilogram body weight for unbound riociguat/M1; CI: confidence interval; CV: coefficient of variation.
In study I, individuals with severe renal impairment received riociguat 0.5 mg, and therefore pharmacokinetic concentrations recorded for these individuals were normalized to a 1.0-mg dose before analysis; all other participants in both studies received riociguat 1.0 mg.